New Research Links Aging Brain Waste Clearance Failure to Alzheimer's Causes

As we age, maintaining a household often becomes a laborious task, but our brains face a similar challenge: a declining self-cleaning mechanism. This system, known as the glymphatic system, is responsible for flushing out toxic waste products that accumulate in the brain daily. However, its efficiency diminishes significantly with age, a failure now linked by a growing number of scientists to the root causes of Alzheimer's and Parkinson's diseases.

By failing to clear specific proteins—amyloid-beta in Alzheimer's and alpha-synuclein in Parkinson's—the brain allows these toxic substances to build up and destroy brain cells. This discovery is particularly urgent following the recent revelation that drugs previously hailed as breakthrough treatments for Alzheimer's, such as donanemab and lecanemab, may be practically ineffective. An analysis by experts at the Cochrane Collaboration of 17 studies concluded these medications make no meaningful difference, a finding that aligns with the National Institute of Health and Care Excellence's (NICE) decision last year to reject their use in the NHS due to limited efficacy, high costs, and side effects like brain swelling.

Scientists are now investigating whether enhancing the glymphatic system offers a viable alternative. Research published in the Journal of Alzheimer's Disease in 2019 highlighted a critical behavioral factor: patients with dementia spend considerably more time sleeping on their backs than healthy individuals. Discovered in 2012 at the University of Rochester, New York, the glymphatic system operates most effectively during the night, particularly during deep sleep when the brain is most restful. Sleeping position may therefore play a significant role in the system's ability to flush out waste.

To accelerate the search for effective treatments, researchers are identifying existing safe human drugs that could boost this cleansing process. Last year, a trial in China involving the anaesthetic dexmedetomidine found that low doses increased glymphatic activity in mice and significantly reduced brain inflammation caused by rogue proteins, as reported in the American Chemical Society Nano. Dexmedetomidine was selected for its ability to induce the deepest form of slumber. In March, US scientists demonstrated that combining dexmedetomidine with midodrine, a medication for low blood pressure that may aid fluid flow, increased glymphatic-system activity by approximately 10 per cent, thereby accelerating the removal of these toxic proteins in patients.

There is also promising news for Parkinson's disease. Current therapies merely minimize symptoms and lose effectiveness over time. This month, Australian researchers announced that a drug already approved for human use can enhance glymphatic cleansing and lower toxic protein levels in Parkinson's patients. Zhao Yan, a scientist at Swinburne University of Technology in Melbourne, presented findings at the Oxford Glymphatic and Brain Clearance Symposium stating that a substance dubbed compound X produced dramatic results in mice with Parkinson's, improving balance and mobility in 80 per cent of the subjects.

Researchers are racing to initiate human trials within the next year, targeting a breakthrough that could halt the progression of Alzheimer's and Parkinson's. Ian Harrison, a principal research fellow at University College London and one of the UK's foremost experts on the glymphatic system, identifies Aquaporin-4 as the critical channel responsible for flushing fluid in and out of the brain. The stakes are high: when this channel is blocked in animal models, subjects rapidly manifest the hallmarks of these devastating diseases. Harrison warns that experimental inhibition of the glymphatic system triggers a dangerous accumulation of amyloid-beta, a protein that disrupts cellular communication and drives Alzheimer's pathology.

"The main channel of the glymphatic system, which enables fluid to flow in and out of the brain, is called Aquaporin-4," Harrison told the Mail. "When this is blocked in animals with Alzheimer's and Parkinson's, 'they quickly show symptoms of these diseases,' he says." In Parkinson's specifically, the system's failure allows abnormal alpha-synuclein to pile up, attacking dopamine-producing cells in the mid-brain. This destruction of dopamine-producing neurons directly causes the motor symptoms associated with the condition. "This attacks cells in the mid-brain that produce dopamine [a chemical messenger that regulates movement] – and it is a lack of dopamine that causes the neurological symptoms of Parkinson's," Harrison explains.

The medical community is now hunting for drugs that accelerate Aquaporin-4 function to prevent toxic protein build-up before it starts. Simultaneously, Harrison's team is testing novel compounds designed to enhance sleep quality, a vital factor because the glymphatic system operates most vigorously during deep non-REM and slow-wave sleep. "Ordinary sleeping pills don't work. They increase sleep duration but not the quality of sleep, whereas the glymphatic system works during the deepest forms of sleep," Harrison emphasizes.

Beyond medication, surgical interventions are emerging as a potent solution. Recent reports from China highlight keyhole surgery capable of restoring cognitive and physical health in dementia patients. Originally developed to treat lymphoedema caused by fluid buildup after lymph node removal, the procedure involves rerouting lymphatic vessels to neighboring veins. In the context of dementia, surgeons perform this bypass in the neck to "unblock" the dysfunctional glymphatic flow, effectively enhancing the brain's ability to clear damaging proteins.

Lifestyle modifications offer another frontline defense. "Decent duration and quality of sleep appear to be particularly important," Harrison states. A 2015 study published in the Journal of Neuroscience revealed that sleeping position matters significantly; rats sleeping curled on their right sides achieved optimal waste removal, outperforming those sleeping on their backs or stomachs. Conversely, a 2019 study in the Journal of Alzheimer's Disease found that dementia patients spend considerably more time sleeping on their backs than healthy individuals. Physical activity further bolsters the system. Harrison notes that mice with free access to running wheels exhibit markedly higher glymphatic activity due to improved fluid flow. A study in Nature Communications last year confirmed this benefit in humans, showing that volunteers who trained daily on exercise bikes for three months displayed significantly improved glymphatic efficiency and reduced brain inflammation on MRI scans.

Nutrition plays a pivotal role as well. A Mediterranean diet, rich in vegetables, fruit, wholegrains, beans, nuts, fish, and olive oil, may supercharge the system. As reported earlier this month by Critical Reviews in Food Science and Nutrition, these foods are dense in antioxidants, omega-3s, vitamins, zinc, and magnesium. "These nutrients together may boost the activity of the Aquaporin-4 channel, as well as reducing brain inflammation and fostering deep sleep," the findings suggest.

Conversely, researchers caution that consuming high-fat diets and drinking excessive amounts of alcohol correlates with diminished Aquaporin-4 activity.

However, a significant divide exists within the scientific community regarding whether enhancing the glymphatic system can effectively halt the progression of Alzheimer's and Parkinson's diseases.

Professor Bart De Strooper, who established the UK Dementia Research Institute at University College London, offered a measured perspective: "The glymphatic system represents an exciting frontier in research, yet it remains far from settled science."

He emphasized the limitations of current data, noting, "Most of the evidence so far comes from mouse studies. We should be careful not to overstate what we know, especially when it comes to the human brain, which is vastly larger and more complex than a mouse brain."

Professor De Strooper further highlighted the controversy surrounding the connection between rest and neural waste removal, stating, "While the link between sleep and brain clearance is appealing, it remains scientifically controversial."

Taking a more definitive stance, Robert Howard, a professor of old-age psychiatry at University College London, declared, "There are absolutely no data to convincingly support the idea that the glymphatic system, or its failure, are somehow linked to risk for Alzheimer's."

In his final assessment, Professor De Strooper concluded that while this field holds promise, its potential application is limited: "This is a promising research direction, but at best it might become part of a broader strategy to slow disease."

He illustrated the current stage of understanding with a vivid analogy: "We are still at the stage of trying to understand the plumbing, not yet at the stage of prescribing the repair.